TB-500 (Thymosin Beta-4) has strong preclinical evidence for tissue repair across multiple injury models, including cardiac, skin, and corneal tissue. Human clinical data is sparse and largely confined to cardiac applications. The gap between animal and human evidence is larger than commonly represented in lay discussions.
How strong is the preclinical evidence for TB-500?
Thymosin Beta-4 preclinical research is extensive relative to most peptides in this space. Cardioprotection studies in rodent infarction models, corneal wound healing trials, and dermal repair experiments all show consistent positive effects. The biological mechanism — actin sequestration and promotion of cell migration — is well-characterised and provides a credible basis for the observed effects.
What human data actually exists?
The most substantial human data for TB-500 comes from cardiac applications, specifically post-myocardial infarction recovery trials. These are small phase I/II studies, not large RCTs. For the musculoskeletal and general tissue repair applications that most non-clinical users focus on, human controlled data is essentially non-existent. This does not mean the effects are absent — it means they have not been tested at the standard required to establish them.